A Phase 1 study of UCN-01 in combination with irinotecan in patients with resistant solid tumor malignancies

UCN-01 (7-hydroxystaurosporine) is a multi-targeted protein kinase inhibitor that exhibits synergistic activity with DNA-damaging agents in preclinical studies. We conducted a Phase I study to determine the maximum-tolerated dose (MTD), dose-limiting toxicity (DLT), pharmacokinetic, and pharmacodynamic effects of UCN-01 and irinotecan in patients with resistant solid tumors.Patients received irinotecan (75-125 mg/m(2) IV on days 1, 8, 15, 22)...